2025 Q2 -tulosraportti
138 päivää sittenTarjoustasot
Oslo Børs
Määrä
Osto
21 629
Myynti
Määrä
10 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 000 | - | - | ||
| 25 000 | - | - | ||
| 4 434 | - | - | ||
| 7 946 | - | - | ||
| 45 | - | - |
Ylin
1,25VWAP
Alin
1,114VaihtoMäärä
5 4 358 140
VWAP
Ylin
1,25Alin
1,114VaihtoMäärä
5 4 358 140
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 15.2.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·5 t sitten · Muokattuhttps://www.youtube.com/watch?v=gEeDZ9vMKQI An interesting interview with CEO Erik if one wants a little extra input
·1 t sittenCan add this one that gives a good and short explanation of where and what they are today (des 25): https://tv.finansavisen.no/nb/watch/5675
·5 t sittenWhat happened to this stock? 😅 have they gone bankrupt or what?
·6 t sittenHas anyone been informed about where we can trade tomorrow?
·5 t sittenThe share is trading as normal... Are you thinking about the subscription rights?
·8 t sittenFound online today: As of January 12, 2026, Circio Holding ASA's market capitalization is significantly lower than billion amounts, but the company's management and analysts see a potential for significant value creation, especially if their circular RNA (circRNA) technology succeeds. Current status and challenges Current market capitalization: The company's market capitalization has recently been very low, with estimates around 63 million NOK in August 2024 and 207 million NOK at the end of 2022. An analysis from Simply Wall Street in September 2024 estimated a market capitalization of only 20.5 million NOK. This is far from billion levels. Financial challenges: Circio has had negative equity and has had to carry out several share issues to secure operations, which has led to significant dilution for existing shareholders. The company recently invited to a webcast to provide information about a planned share issue of up to 50 million kroner. Potential for billion-dollar value Technology potential: Circio is developing a new platform for circular RNA (circVec technology) for gene and cell therapy. This is a field with enormous global potential, where large markets are worth tens of billions of dollars. Successful breakthroughs in biotechnology can trigger enormous value increases. Analyst assessments: A discounted cash flow (DCF) analysis from Simply Wall Street in September 2024 suggested a "fair value" of over 1200 NOK per share, which indicates a theoretical potential for a much higher market capitalization if all future cash flow is realized. Statements from management: Previously, the company's management (under the name Targovax) stated that they believe the company could have been worth 100 times more, which reflects the belief in the underlying technology. Industry trends: Large deals and mergers in the RNA field, such as Novartis' acquisition of Avidity for 12 billion USD in 2025, show that there is significant interest and capital in this sector, which could be positive for Circio if they achieve successful partnerships. Conclusion: As of today, Circio is not worth many billions of kroner. The company is an early-stage biotechnology company with significant financial and operational risks. However, they are positioned in a market with very large potential. Should they achieve clinical breakthroughs and land large, strategic partnerships for their technology, it is theoretically possible that the value could rise dramatically and potentially reach billion amounts, but this involves high risk.·7 t sittenI believe management is aware of any potential timing for acquisitions should it become relevant. They are actively building value through collaborations, agreements, and results from studies. If this goes well, there will likely be a price increase along the way, and some will surely find that good enough. Here there are opportunities for everyone.- ·9 t sittenWebcast from USA on the 15th. He's probably going over to the unit to sign a deal then? Then he'll do a webcast on the news.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
138 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sitten · Muokattuhttps://www.youtube.com/watch?v=gEeDZ9vMKQI An interesting interview with CEO Erik if one wants a little extra input·1 t sittenCan add this one that gives a good and short explanation of where and what they are today (des 25): https://tv.finansavisen.no/nb/watch/5675
- ·5 t sittenWhat happened to this stock? 😅 have they gone bankrupt or what?
- ·6 t sittenHas anyone been informed about where we can trade tomorrow?·5 t sittenThe share is trading as normal... Are you thinking about the subscription rights?
- ·8 t sittenFound online today: As of January 12, 2026, Circio Holding ASA's market capitalization is significantly lower than billion amounts, but the company's management and analysts see a potential for significant value creation, especially if their circular RNA (circRNA) technology succeeds. Current status and challenges Current market capitalization: The company's market capitalization has recently been very low, with estimates around 63 million NOK in August 2024 and 207 million NOK at the end of 2022. An analysis from Simply Wall Street in September 2024 estimated a market capitalization of only 20.5 million NOK. This is far from billion levels. Financial challenges: Circio has had negative equity and has had to carry out several share issues to secure operations, which has led to significant dilution for existing shareholders. The company recently invited to a webcast to provide information about a planned share issue of up to 50 million kroner. Potential for billion-dollar value Technology potential: Circio is developing a new platform for circular RNA (circVec technology) for gene and cell therapy. This is a field with enormous global potential, where large markets are worth tens of billions of dollars. Successful breakthroughs in biotechnology can trigger enormous value increases. Analyst assessments: A discounted cash flow (DCF) analysis from Simply Wall Street in September 2024 suggested a "fair value" of over 1200 NOK per share, which indicates a theoretical potential for a much higher market capitalization if all future cash flow is realized. Statements from management: Previously, the company's management (under the name Targovax) stated that they believe the company could have been worth 100 times more, which reflects the belief in the underlying technology. Industry trends: Large deals and mergers in the RNA field, such as Novartis' acquisition of Avidity for 12 billion USD in 2025, show that there is significant interest and capital in this sector, which could be positive for Circio if they achieve successful partnerships. Conclusion: As of today, Circio is not worth many billions of kroner. The company is an early-stage biotechnology company with significant financial and operational risks. However, they are positioned in a market with very large potential. Should they achieve clinical breakthroughs and land large, strategic partnerships for their technology, it is theoretically possible that the value could rise dramatically and potentially reach billion amounts, but this involves high risk.·7 t sittenI believe management is aware of any potential timing for acquisitions should it become relevant. They are actively building value through collaborations, agreements, and results from studies. If this goes well, there will likely be a price increase along the way, and some will surely find that good enough. Here there are opportunities for everyone.
- ·9 t sittenWebcast from USA on the 15th. He's probably going over to the unit to sign a deal then? Then he'll do a webcast on the news.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
21 629
Myynti
Määrä
10 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 000 | - | - | ||
| 25 000 | - | - | ||
| 4 434 | - | - | ||
| 7 946 | - | - | ||
| 45 | - | - |
Ylin
1,25VWAP
Alin
1,114VaihtoMäärä
5 4 358 140
VWAP
Ylin
1,25Alin
1,114VaihtoMäärä
5 4 358 140
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 15.2.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
Datan lähde: FactSet, Quartr
2025 Q2 -tulosraportti
138 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 15.2.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sitten · Muokattuhttps://www.youtube.com/watch?v=gEeDZ9vMKQI An interesting interview with CEO Erik if one wants a little extra input·1 t sittenCan add this one that gives a good and short explanation of where and what they are today (des 25): https://tv.finansavisen.no/nb/watch/5675
- ·5 t sittenWhat happened to this stock? 😅 have they gone bankrupt or what?
- ·6 t sittenHas anyone been informed about where we can trade tomorrow?·5 t sittenThe share is trading as normal... Are you thinking about the subscription rights?
- ·8 t sittenFound online today: As of January 12, 2026, Circio Holding ASA's market capitalization is significantly lower than billion amounts, but the company's management and analysts see a potential for significant value creation, especially if their circular RNA (circRNA) technology succeeds. Current status and challenges Current market capitalization: The company's market capitalization has recently been very low, with estimates around 63 million NOK in August 2024 and 207 million NOK at the end of 2022. An analysis from Simply Wall Street in September 2024 estimated a market capitalization of only 20.5 million NOK. This is far from billion levels. Financial challenges: Circio has had negative equity and has had to carry out several share issues to secure operations, which has led to significant dilution for existing shareholders. The company recently invited to a webcast to provide information about a planned share issue of up to 50 million kroner. Potential for billion-dollar value Technology potential: Circio is developing a new platform for circular RNA (circVec technology) for gene and cell therapy. This is a field with enormous global potential, where large markets are worth tens of billions of dollars. Successful breakthroughs in biotechnology can trigger enormous value increases. Analyst assessments: A discounted cash flow (DCF) analysis from Simply Wall Street in September 2024 suggested a "fair value" of over 1200 NOK per share, which indicates a theoretical potential for a much higher market capitalization if all future cash flow is realized. Statements from management: Previously, the company's management (under the name Targovax) stated that they believe the company could have been worth 100 times more, which reflects the belief in the underlying technology. Industry trends: Large deals and mergers in the RNA field, such as Novartis' acquisition of Avidity for 12 billion USD in 2025, show that there is significant interest and capital in this sector, which could be positive for Circio if they achieve successful partnerships. Conclusion: As of today, Circio is not worth many billions of kroner. The company is an early-stage biotechnology company with significant financial and operational risks. However, they are positioned in a market with very large potential. Should they achieve clinical breakthroughs and land large, strategic partnerships for their technology, it is theoretically possible that the value could rise dramatically and potentially reach billion amounts, but this involves high risk.·7 t sittenI believe management is aware of any potential timing for acquisitions should it become relevant. They are actively building value through collaborations, agreements, and results from studies. If this goes well, there will likely be a price increase along the way, and some will surely find that good enough. Here there are opportunities for everyone.
- ·9 t sittenWebcast from USA on the 15th. He's probably going over to the unit to sign a deal then? Then he'll do a webcast on the news.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
21 629
Myynti
Määrä
10 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 000 | - | - | ||
| 25 000 | - | - | ||
| 4 434 | - | - | ||
| 7 946 | - | - | ||
| 45 | - | - |
Ylin
1,25VWAP
Alin
1,114VaihtoMäärä
5 4 358 140
VWAP
Ylin
1,25Alin
1,114VaihtoMäärä
5 4 358 140
Välittäjätilasto
Dataa ei löytynyt